Author

M. C. Mariano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:proteomics· 3 Approach:statistical model· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

A. P. Wiita· 3 shared I. D. Ferguson· 3 shared Y.-H. T. Lin· 3 shared C. Driessen· 2 shared A. M. Thornton· 1 shared A. N. Brooks· 1 shared B. C. Hann· 1 shared B. G. Barwick· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. P. Wiita

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma

I. D. Ferguson, Y.-H. T. Lin, C. Lam, H. Shao, M. Hale, K. M. Tharp, M. C. Mariano, V. Steri, D. Wang, P. Phojanokong, S. T. Tuomivaara, B. Hann, C. Driessen, B. V. Ness, J. E. Gestwicki, A. P. Wiita

This study identifies allosteric HSP70 inhibitors that overcome proteasome inhibitor resistance in multiple myeloma by targeting mitochondrial HSPA9 and disrupting mitoribosome stability.

bioRxiv · Apr 21, 2020Cancer Biology

Integrated Phosphoproteomics and Transcriptional Classifiers Reveal Hidden RAS Signaling Dynamics in Multiple Myeloma

Y.-H. T. Lin, G. P. Way, B. G. Barwick, M. C. Mariano, M. Marcoulis, I. D. Ferguson, C. Driessen, L. H. Boise, C. S. Greene, A. P. Wiita

The paper uses phosphoproteomics and transcriptomics to analyze RAS signaling in multiple myeloma, identifying distinct signaling patterns and clinical outcomes associated with NRAS and KRAS mutations.

bioRxiv · Feb 28, 2019Cancer Biology

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

H. H.-L. Huang, I. D. Ferguson, A. M. Thornton, C. Y. T. Lam, Y.-H. T. Lin, P. Bastola, P. Choudhry, M. C. Mariano, M. D. Marcoulis, J. Malato, P. Phojanakong, T. G. Martin, J. L. Wolf, S. W. Wong, N. Shah, , A. P. Wiita

The paper shows proteasome inhibitors modulate splicing in multiple myeloma, revealing spliceosome inhibition as a therapeutic target.

bioRxiv · Feb 3, 2019Cancer Biology